Clonal Selection with RAS Pathway Activation Mediates Selective FLT3 Inhibition in Acute Myeloid Leukemia

Cancer Discovery

9, 1050-1063

DOI: 10.1158/2159-8290.cd-18-1453

Citation Report

#	Article	IF	Citations
1	Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?. Cancer Discovery, 2019, 9, 998-1000.	7.7	5
2	Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?. International Journal of Molecular Sciences, 2019, 20, 3429.	1.8	39
3	Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. New England Journal of Medicine, 2019, 381, 1728-1740.	13.9	796
4	Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia. Expert Review of Clinical Pharmacology, 2019, 12, 841-849.	1.3	14
5	CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Cancers, 2019, 11, 1358.	1.7	98
6	FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy. International Journal of Molecular Sciences, 2019, 20, 4563.	1.8	12
7	MRD evaluation of AML in clinical practice: are we there yet?. Hematology American Society of Hematology Education Program, 2019, 2019, 557-569.	0.9	27
8	Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. Nature Communications, 2019, 10, 5386.	5.8	53
9	Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia. Journal of Oncology, 2019, 2019, 1-8.	0.6	3
10	Methyltransferase DNMT3B in leukemia. Leukemia and Lymphoma, 2020, 61, 263-273.	0.6	6
11	Single-cell analysis based dissection of clonality in myelofibrosis. Nature Communications, 2020, 11, 73.	5.8	46
12	FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Science, 2020, 111, 312-322.	1.7	124
13	Single-cell sequencing in hematology. Current Opinion in Oncology, 2020, 32, 139-145.	1.1	15
14	Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia. Cancer Discovery, 2020, 10, 214-231.	7.7	27
15	Molecular Pathways and Potential for Targeted Therapies in the Treatment of Early T-cell Precursor Acute Lymphoblastic Leukemia. Advances in Molecular Pathology, 2020, 3, 41-48.	0.2	0
16	Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nature Communications, 2020, 11, 5327.	5.8	208
17	Targeted Single-Cell RNA and DNA Sequencing With Fluorescence-Activated Droplet Merger. Analytical Chemistry, 2020, 92, 14616-14623.	3.2	9
18	Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leukemia and Lymphoma, 2020, 61, 3243-3246.	0.6	3

#	Article	IF	Citations
19	Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2020, 63, 12403-12428.	2.9	48
20	Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments. Cells, 2020, 9, 2493.	1.8	49
21	MLL-menin and FLT3 inhibitors team up for AML. Blood, 2020, 136, 2369-2370.	0.6	2
22	Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation. Cancers, 2020, 12, 3511.	1.7	13
23	Phase 1 study of combinatorial sorafenib, <scp>Gâ€CSF</scp>, and plerixafor treatment in relapsed/refractory, <scp>FLT3â€ITD</scp>â€mutated acute myelogenous leukemia patients. American Journal of Hematology, 2020, 95, 1296-1303.	2.0	22
24	Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Biomedicines, 2020, 8, 245.	1.4	35
25	Cutting Edge Molecular Therapy for Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2020, 21, 5114.	1.8	5
26	Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. Journal of Hematology and Oncology, 2020, 13, 103.	6.9	69
27	Quizartinib for the treatment of acute myeloid leukemia. Expert Opinion on Pharmacotherapy, 2020, 21, 2077-2090.	0.9	14
28	The critical roles of somatic mutations and environmental tumor-promoting agents in cancer risk. Nature Genetics, 2020, 52, 1139-1143.	9.4	73
29	Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome. Drug Resistance Updates, 2020, 53, 100730.	6.5	22
30	Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature, 2020, 587, 477-482.	13.7	304
31	Emergence of BCRâ€“ABL1 Fusion in AML Postâ€“FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance â€“ A Case Series. Frontiers in Oncology, 2020, 10, 588876.	1.3	13
32	FLT3 Inhibition in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S5-S6.	0.2	4
33	Single-cell sequencing techniques from individual to multiomics analyses. Experimental and Molecular Medicine, 2020, 52, 1419-1427.	3.2	136
34	FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. Frontiers in Oncology, 2020, 10, 612880.	1.3	92
35	Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo. Leukemia, 2020, 35, 2017-2029.	3.3	27
36	Treatment-free remission in patients with chronic myeloid leukaemia. Nature Reviews Clinical Oncology, 2020, 17, 493-503.	12.5	33

#	Article	IF	Citations
37	Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Advances, 2020, 4, 1894-1905.	2.5	129
38	Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia. Cancers, 2020, 12, 1574.	1.7	10
39	How I treat relapsed or refractory AML. Blood, 2020, 136, 1023-1032.	0.6	64
40	Mutations predictive of hyperactive Ras signaling correlate with inferior survival across high-risk pediatric acute leukemia. Translational Pediatrics, 2020, 9, 43-50.	0.5	4
41	CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-Î² Signaling. Cancers, 2020, 12, 1737.	1.7	8
42	From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. Cancers, 2020, 12, 357.	1.7	11
43	Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML. International Journal of Molecular Sciences, 2020, 21, 1537.	1.8	37
44	Driver mutations in acute myeloid leukemia. Current Opinion in Hematology, 2020, 27, 49-57.	1.2	44
45	Clonal competition within complex evolutionary hierarchies shapes AML over time. Nature Communications, 2020, 11, 579.	5.8	21
46	Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discovery, 2020, 10, 506-525.	7.7	212
47	Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients. Journal of Oncology Pharmacy Practice, 2020, 26, 1200-1212.	0.5	4
48	A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITDâ€“mutant acute myeloid leukemia. Blood Advances, 2020, 4, 1711-1721.	2.5	30
49	Advancing Cancer Research and Medicine with Single-Cell Genomics. Cancer Cell, 2020, 37, 456-470.	7.7	187
50	New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. Blood, 2020, 135, 1365-1376.	0.6	93
51	How I treat acute myeloid leukemia in the era of new drugs. Blood, 2020, 135, 85-96.	0.6	172
52	Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood, 2020, 135, 791-803.	0.6	412
53	Gilteritinib: potent targeting of FLT3 mutations in AML. Blood Advances, 2020, 4, 1178-1191.	2.5	86
54	Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Blood Advances, 2020, 4, 514-524.	2.5	54

#	Article	IF	Citations
55	Single-cell mutational profiling enhances the clinical evaluation of AML MRD. Blood Advances, 2020, 4, 943-952.	2.5	63
56	The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a034975.	2.9	8
57	Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica, 2021, 106, 1034-1046.	1.7	75
58	Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy. Leukemia, 2021, 35, 712-723.	3.3	10
59	Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nature Reviews Clinical Oncology, 2021, 18, 244-256.	12.5	138
60	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. Blood Cancer Discovery, 2021, 2, 125-134.	2.6	50
61	Genetic heterogeneity and clonal evolution in acute myeloid leukemia. Current Opinion in Hematology, 2021, 28, 64-70.	1.2	13
62	Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, 57-65.	0.8	118
63	Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITDâ€“Driven Acute Myeloid Leukemia. Cancer Discovery, 2021, 11, 1582-1599.	7.7	35
64	Oncogenic N-Ras Mitigates Oxidative Stressâ€“Induced Apoptosis of Hematopoietic Stem Cells. Cancer Research, 2021, 81, 1240-1251.	0.4	7
65	Bypass, Escape, or Mutate: The Resistant Clones in Midostaurin-treated FLT3-ITD AML. , 2021, 18, .		0
66	Prognostic mutation constellations in acute myeloid leukaemia and myelodysplastic syndrome. Current Opinion in Hematology, 2021, 28, 101-109.	1.2	1
67	Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Future Oncology, 2021, 17, 215-227.	1.1	0
68	Future Developments: Novel Agents. Hematologic Malignancies, 2021, , 293-315.	0.2	1
69	Bacon-Wrapped Chemo: Can Liposomal Cytarabine/Daunomycin Improve Outcomes for Children With Newly Diagnosed AML Versus Conventional Therapy?. , 2021, 18, .		0
70	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Science Advances, 2021, 7, .	4.7	28
71	The transcriptional regulation of normal and malignant blood cell development. FEBS Journal, 2022, 289, 1240-1255.	2.2	19
72	Advances and unanswered questions in management of acute myeloid leukemia in older adults: A glimpse into the future. Journal of Geriatric Oncology, 2021, 12, 980-984.	0.5	3

#	Article	IF	Citations
73	Unraveling a T-ALL Tapestri. Blood, 2021, 137, 726-727.	0.6	0
74	Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach. Cancers, 2021, 13, 841.	1.7	5
75	Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?. Best Practice and Research in Clinical Haematology, 2021, 34, 101246.	0.7	0
76	OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 48.	2.8	5
77	The prognosis and durable clearance of <scp>RAS</scp> mutations in patients with acute myeloid leukemia receiving induction chemotherapy. American Journal of Hematology, 2021, 96, E171-E175.	2.0	6
78	Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. Blood Advances, 2021, 5, 1437-1441.	2.5	15
79	Time to Move to the Single-Cell Level: Applications of Single-Cell Multi-Omics to Hematological Malignancies and WaldenstrÃ¶mâ€™s Macroglobulinemiaâ€”A Particularly Heterogeneous Lymphoma. Cancers, 2021, 13, 1541.	1.7	8
81	Modeling and targeting of erythroleukemia by hematopoietic genome editing. Blood, 2021, 137, 1628-1640.	0.6	25
82	Which novel agents will have a clinically meaningful impact in AML at diagnosis?. Best Practice and Research in Clinical Haematology, 2021, 34, 101257.	0.7	3
83	Mechanisms of Resistence of New Target Drugs in Acute Myeloid Leukemia. , 0, , .		0
84	Traipsing Through Muddy Waters. Hematology/Oncology Clinics of North America, 2021, 35, 337-352.	0.9	0
85	Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome. Pathology, 2021, 53, 328-338.	0.3	6
86	The importance of Ras in drug resistance in cancer. British Journal of Pharmacology, 2022, 179, 2844-2867.	2.7	26
87	A noncanonical <scp>FLT3</scp> gatekeeper mutation disrupts gilteritinib binding and confers resistance. American Journal of Hematology, 2021, 96, E226-E229.	2.0	11
88	Towards precision medicine for AML. Nature Reviews Clinical Oncology, 2021, 18, 577-590.	12.5	138
89	The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. Cancers, 2021, 13, 2458.	1.7	7
90	FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review. International Journal of Molecular Sciences, 2021, 22, 5873.	1.8	9
91	FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer Journal, 2021, 11, 104.	2.8	61

#	Article	IF	Citations
92	Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clinical Cancer Research, 2021, 27, 4003-4011.	3.2	7
93	Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression. Blood, 2021, 138, 2244-2255.	0.6	20
94	The contribution of single-cell analysis of acute leukemia in the therapeutic strategy. Biomarker Research, 2021, 9, 50.	2.8	9
95	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood, 2021, 137, 3093-3104.	0.6	91
96	A precision medicine classification for treatment of acute myeloid leukemia in older patients. Journal of Hematology and Oncology, 2021, 14, 96.	6.9	5
97	The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. Cancer Cell, 2021, 39, 999-1014.e8.	7.7	62
98	Single-cell sequencing technology in tumor research. Clinica Chimica Acta, 2021, 518, 101-109.	0.5	15
99	The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents. Acta Haematologica, 2021, 144, 649-659.	0.7	1
100	Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 720-723.	0.2	0
101	The Importance of Being PI3K in the RAS Signaling Network. Genes, 2021, 12, 1094.	1.0	28
102	The beginning of a new therapeutic era in acute myeloid leukemia. EJHaem, 2021, 2, 823-833.	0.4	3
103	Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance. Current Treatment Options in Oncology, 2021, 22, 76.	1.3	6
104	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia, 2022, 36, 90-99.	3.3	42
105	Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML. Cancer Genetics, 2021, 256-257, 68-76.	0.2	2
106	AML-149: Efficacy and Safety of Azacytidine in Combination with Fludarabine and High-Dose Cytarabine with G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Open-Label, Phase II Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S284.	0.2	0
107	Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies. Frontiers in Oncology, 2021, 11, 748250.	1.3	7
108	Clonal Architecture and Evolutionary Dynamics in Acute Myeloid Leukemias. Cancers, 2021, 13, 4887.	1.7	11
109	Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia. Cancers, 2021, 13, 4646.	1.7	8

#	Article	IF	Citations
110	A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia. Haematologica, 2021, 106, 1022-1033.	1.7	10
111	Treatment of Relapsed and Refractory AML: Non-intensive Approach in Unfit Patients. Hematologic Malignancies, 2021, , 241-254.	0.2	0
113	Acquired BCR-ABL1 fusion and IDH1 clonal evolution following BCL2 inhibitor treatment in refractory acute myeloid leukemia. Leukemia Research, 2021, 100, 106494.	0.4	1
114	Current Approaches to Transplantation for FLT3-ITD AML. Current Hematologic Malignancy Reports, 2020, 15, 1-8.	1.2	6
115	Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia. Drug Resistance Updates, 2020, 52, 100703.	6.5	25
118	TP-0903 is active in models of drug-resistant acute myeloid leukemia. JCI Insight, 2020, 5, .	2.3	14
119	The growing landscape of FLT3 inhibition in AML. Hematology American Society of Hematology Education Program, 2019, 2019, 539-547.	0.9	30
120	Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells. Oncotarget, 2020, 11, 943-955.	0.8	19
121	Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia. Oncotarget, 2020, 11, 2233-2245.	0.8	4
122	The Evolving AML Genomic Landscape: Therapeutic Implications. Current Cancer Drug Targets, 2020, 20, 532-544.	0.8	8
123	FLT3 Inhibition in Acute Myeloid Leukaemia â€“ Current Knowledge and Future Prospects. Current Cancer Drug Targets, 2020, 20, 513-531.	0.8	10
124	FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives. Minerva Medica, 2020, 111, 427-442.	0.3	14
125	A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia. Haematologica, 2022, 107, 77-85.	1.7	20
126	Differentiation therapy of myeloid leukemia: four decades of development. Haematologica, 2021, 106, 1-13.	1.7	27
127	Current and Emerging Therapies for Acute Myeloid Leukemia. Cancer Treatment and Research, 2021, 181, 57-73.	0.2	2
128	Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission. Bone Marrow Transplantation, 2022, 57, 95-105.	1.3	8
129	Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia. Cancers, 2021, 13, 5055.	1.7	4
130	Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematology,the, 2021, 8, e922-e933.	2.2	27

#	Article	IF	Citations
131	Somatic variant analysis suite: copy number variation clonal visualization online platform for large-scale single-cell genomics. Briefings in Bioinformatics, 2021, , .	3.2	9
132	BETing on rational combination therapy in mutant FLT3 acute myeloid leukemia. Haematologica, 2021, 106, 931-932.	1.7	0
133	The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutationâ€“positive relapsed/refractory acute myeloid leukemia. Cancer Medicine, 2021, 10, 797-805.	1.3	7
134	Understanding FLT3 Inhibitor Resistance to Rationalize Combinatorial AML Therapies. Blood Cancer Discovery, 2021, 2, 113-115.	2.6	4
135	AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia. Haematologica, 2022, 107, 1311-1322.	1.7	15
137	The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML. Leukemia, 2021, , .	3.3	12
138	A review of FLT3 inhibitors in acute myeloid leukemia. Blood Reviews, 2022, 52, 100905.	2.8	50
141	Single-Cell Sequencing: Biological Insight and Potential Clinical Implications in Pediatric Leukemia. Cancers, 2021, 13, 5658.	1.7	3
142	Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nature Cancer, 2021, 2, 1204-1223.	5.7	42
143	Oncogenic KRAS: Signaling and Drug Resistance. Cancers, 2021, 13, 5599.	1.7	25
144	Momelotinib is a highly potent inhibitor of FLT3-mutant AML. Blood Advances, 2022, 6, 1186-1192.	2.5	10
145	Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 810387.	1.3	7
147	Single-Cell Technologies to Decipher the Immune Microenvironment in Myeloid Neoplasms: Perspectives and Opportunities. Frontiers in Oncology, 2021, 11, 796477.	1.3	0
148	Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML. Translational Oncology, 2022, 18, 101354.	1.7	9
149	Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Advances, 2022, 6, 2144-2155.	2.5	28
150	Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach. Bioorganic Chemistry, 2022, 121, 105675.	2.0	10
152	Role of Biomarkers in FLT3 AML. Cancers, 2022, 14, 1164.	1.7	15
153	Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduction and Targeted Therapy, 2022, 7, 51.	7.1	54

#	Article	IF	Citations
154	Single cell proteogenomic sequencing identifies a relapseâ€fated AML subclone carrying FLT3 â€ITD with CNâ€LOH at chr13q. EJHaem, 0, , .	0.4	1
155	Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2022, 23, 2362.	1.8	5
156	A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib. Molecular Cancer, 2022, 21, 66.	7.9	18
157	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. Leukemia, 2022, 36, 1237-1252.	3.3	12
158	Which FLT3 Inhibitor for Treatment of AML?. Current Treatment Options in Oncology, 2022, 23, 359-380.	1.3	5
159	Monitoring of Leukemia Clones in B-cell Acute Lymphoblastic Leukemia at Diagnosis and During Treatment by Single-cell DNA Amplicon Sequencing. HemaSphere, 2022, 6, e700.	1.2	8
160	Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents. Cancers, 2022, 14, 1689.	1.7	6
161	Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells. Nature Communications, 2022, 13, 1624.	5.8	11
163	The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms. Molecular Cancer Therapeutics, 2022, 21, 844-854.	1.9	13
164	Understanding Drug Sensitivity and Tackling Resistance in Cancer. Cancer Research, 2022, 82, 1448-1460.	0.4	24
165	Single-Cell Sequencing: Ariadneâ€™s Thread in the Maze of Acute Myeloid Leukemia. Diagnostics, 2022, 12, 996.	1.3	2
166	Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia. Experimental Hematology, 2022, 111, 13-24.	0.2	6
168	Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm- overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement. Pathology, 2022, , .	0.3	2
169	Pediatric Acute Myeloid Leukemia Enters the Molecularly Targeted Era Via FLT3 Inhibition. Journal of Clinical Oncology, 2022, 40, 2058-2060.	0.8	1
170	FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation. International Journal of Hematology, 2022, 116, 341-350.	0.7	2
171	Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Advances, 2022, 6, 5345-5355.	2.5	24
172	FLT3-targeted treatment for acute myeloid leukemia. International Journal of Hematology, 2022, 116, 351-363.	0.7	10
173	The translational challenges of precision oncology. Cancer Cell, 2022, 40, 458-478.	7.7	38

#	Article	IF	Citations
174	Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia. Blood Cancer Discovery, 2022, 3, 316-329.	2.6	20
175	Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia. Molecular Cancer Therapeutics, 2022, 21, 1125-1135.	1.9	4
176	Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development. Cancer Letters, 2022, 539, 215716.	3.2	8
177	FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms. RSC Medicinal Chemistry, 2022, 13, 798-816.	1.7	7
178	The Promise of Single-cell Technology in Providing New Insights Into the Molecular Heterogeneity and Management of Acute Lymphoblastic Leukemia. HemaSphere, 2022, 6, e734.	1.2	4
179	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer Journal, 2022, 12, .	2.8	23
180	Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways. Molecules, 2022, 27, 3513.	1.7	12
181	Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells. Life, 2022, 12, 811.	1.1	16
182	New Therapeutic Strategies for Adult Acute Myeloid Leukemia. Cancers, 2022, 14, 2806.	1.7	15
183	Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer Journal, 2022, 12, .	2.8	9
184	A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations. Acta Haematologica, 2022, 145, 529-536.	0.7	14
185	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. International Journal of Molecular Sciences, 2022, 23, 7839.	1.8	13
186	BMX kinase mediates gilteritinib resistance inFLT3-mutated AML through microenvironmental factors. Blood Advances, 2022, 6, 5049-5060.	2.5	3
187	â€œFLippingâ€•the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors. Cancers, 2022, 14, 3398.	1.7	9
188	Understanding ER homeostasis and the UPR to enhance treatment efficacy of acute myeloid leukemia. Drug Resistance Updates, 2022, 64, 100853.	6.5	10
189	5-Demethylnobiletin Inhibits Cell Proliferation, Downregulates ID1 Expression, Modulates the NF-Î°B/TNF-Î± Pathway and Exerts Antileukemic Effects in AML Cells. International Journal of Molecular Sciences, 2022, 23, 7392.	1.8	3
190	Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology, 2022, 40, 4048-4059.	0.8	73
191	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 2022, 140, 1345-1377.	0.6	805

#	Article	IF	Citations
192	Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper. British Journal of Haematology, 2022, 199, 205-221.	1.2	2
193	Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia. Leukemia, 2022, 36, 2396-2407.	3.3	11
194	Single-cell genomics in AML: extending the frontiers of AML research. Blood, 2023, 141, 345-355.	0.6	14
195	Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling. PLoS Computational Biology, 2022, 18, e1010438.	1.5	1
196	Proliferation and Self-Renewal Are Differentially Sensitive to NRASG12V Oncogene Levels in an Acute Myeloid Leukemia Cell Line. Molecular Cancer Research, 2022, 20, 1646-1658.	1.5	2
197	Leukemias, Lymphomas, and Plasma Cell Disorders. , 2023, , 237-300.		0
198	Developments and challenges of FLT3 inhibitors in acute myeloid leukemia. Frontiers in Oncology, 0, 12, .	1.3	5
199	Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML. Blood Advances, 0, , .	2.5	2
200	Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences, 2022, 51, 507-514.	0.1	0
201	Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines. Cellular Oncology (Dordrecht), 2022, 45, 1005-1018.	2.1	4
202	Implications of <scp>RAS</scp> mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. American Journal of Hematology, 2022, 97, 1599-1606.	2.0	9
203	Emergence of a BCR::ABL1 rearrangement following a uniquely complex clonal evolution pattern in a patient undergoing Fmsâ€like tyrosine kinase 3 inhibitor therapy for acute myeloid leukemia. International Journal of Laboratory Hematology, 2023, 45, .	0.7	0
204	Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure. Cancers, 2022, 14, 4315.	1.7	8
205	Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2023, 41, 756-765.	0.8	35
206	A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. Haematologica, 2023, 108, 705-716.	1.7	2
207	The magnitude of CXCR4 signaling regulates resistance to quizartinib in FLT3/ITD+ cells via RUNX1. Leukemia Research, 2022, , 106983.	0.4	1
209	Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Advances, 2023, 7, 933-942.	2.5	14
210	Single-cell methods in myeloproliferative neoplasms: old questions, new technologies. Blood, 2023, 141, 380-390.	0.6	4

#	Article	IF	Citations
211	Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours. Expert Review of Hematology, 2022, 15, 973-986.	1.0	1
212	Resistance to targeted therapies in acute myeloid leukemia. Clinical and Experimental Metastasis, 2023, 40, 33-44.	1.7	3
213	Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia. Experimental Hematology and Oncology, 2022, 11, .	2.0	4
214	Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO. Leukemia, 2023, 37, 91-101.	3.3	4
215	Targeting Gatekeeper Mutations for Kinase Drug Discovery. Journal of Medicinal Chemistry, 2022, 65, 15540-15558.	2.9	14
216	Cellular distribution of IDH mutations in AML during morphologic remission. Leukemia Research, 2023, 124, 106993.	0.4	0
217	Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches. OncoTargets and Therapy, 0, Volume 15, 1449-1478.	1.0	10
220	FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile. OncoTargets and Therapy, 0, Volume 16, 31-45.	1.0	4
221	Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia. Biomarker Research, 2023, 11, .	2.8	4
223	Application of high-throughput single-nucleus DNA sequencing in pancreatic cancer. Nature Communications, 2023, 14, .	5.8	6
224	An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape. Current Oncology Reports, 2023, 25, 369-378.	1.8	8
225	Ruxolitinib mediates clonal evolution of RAS pathway mutations in MPN. , 0, , .		0
226	PROTACs: Walking through hematological malignancies. Frontiers in Pharmacology, 0, 14, .	1.6	0
229	Emergence of BCR-ABL1 (p190) in Acute Myeloid Leukemia Post-Gilteritinib Therapy. Annals of Laboratory Medicine, 2023, 43, 386-388.	1.2	1
230	Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. International Journal of Molecular Sciences, 2023, 24, 4790.	1.8	5
231	Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance. Cancers, 2023, 15, 1617.	1.7	4
232	Sidestepping SHP2 inhibition. Journal of Experimental Medicine, 2023, 220, .	4.2	1
233	Augmenting Venetoclax Activity Through Signal Transduction in AML. , 2023, 4, 1-12.		4

#	Article	IF	Citations
235	C/EBPÎ± Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stressâ€“Induced Ferroptosis inFLT3-Mutant Leukemia. Cancer Discovery, 2023, 13, 1720-1747.	7.7	19
236	Targeting C/EBPÎ± overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia. Nature Communications, 2023, 14, .	5.8	0
237	A review of treatment options employed in relapsed/refractory AML. Hematology, 2023, 28, .	0.7	6
239	Aptamers against cancer drug resistance: Small fighters switching tactics in the face of defeat. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166720.	1.8	6
256	Clonal evolution in leukemia: preleukemia, evolutionary models, and clinical implications. Genome Instability & Disease, 2023, 4, 227-238.	0.5	0
266	Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia. Annals of Hematology, 0, , .	0.8	0